Grace Kong, MD
Obstetrics & Gynecology · Los Angeles, CANPI 1386836336
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 99 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $523 and has fallen 84.2% since, to $82 in 2025.
Across 99 payments — averaging $18.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$394
- Pfizer$199
- Bayer$148
- Organon$145
- Therapeuticsmd, Inc.$138
- Aspira Women's Health Inc$122
- plus $704 from 18 others
What the payments were for
- Food & beverage$1,851100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 20 | $394 |
| Pfizer | 10 | $199 |
| Bayer | 10 | $148 |
| Organon | 6 | $145 |
| Therapeuticsmd, Inc. | 10 | $138 |
| Aspira Women's Health Inc | 4 | $122 |
| Coopersurgical, Inc. | 5 | $87 |
| Lupin Inc. | 5 | $85 |
| Myovant Sciences Inc. | 3 | $64 |
| Exeltis, USA Inc. | 4 | $64 |
| Evofem Biosciences, Inc. | 4 | $58 |
| Channel Medsystems, Inc. | 2 | $47 |
| Minerva Surgical, Inc | 2 | $46 |
| Merck | 2 | $40 |
| Biogen | 1 | $34 |
| Shield Therapeutics Inc | 2 | $32 |
| Smith+Nephew | 1 | $26 |
| Astellas Pharma US Inc | 1 | $25 |
| Daiichi Sankyo Inc. | 2 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Amgen | 1 | $15 |
| Agile Therapeutics, Inc. | 1 | $12 |
| Covidien LP | 1 | $12 |
| Meditrina | 1 | $11 |
How this compares
$1,851 in reported general payments places this provider in the 75th percentile of 3,784 obstetrics & gynecology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 23 | $976 |
| ValacyclovirValacyclovir Hcl | 12 | $364 |
| ProgesteroneProgesterone, Micronized | 15 | $327 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Los Angeles
- Malcolm MunroLos Angeles$609K
- Ramon YeraLos Angeles$296K
- Ritu SalaniLos Angeles$158K
- Aela PaizLos Angeles$131K
- Roy SilverLos Angeles$57K
- Karen MannLos Angeles$50K
- Sebhat AfeworkLos Angeles$42K
- Nicole BenderLos Angeles$35K
- Christine SterlingLos Angeles$30K
- Steve YuNorthridge$964K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.